Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Insmed Incorporated

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BRIDGEWATER, N.J. , NOV. 5, 2025 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY ANNOUNCED THAT MANAGEMENT WILL PRESENT AT THE FOLLOWING INVESTOR CONFERENCES: JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON, ON TUESDAY, NOVEMBER 18, 2025, AT 8:30 A.M.

INSMED TO PRESENT AT NOVEMBER AND DECEMBER 2025 INVESTOR CONFERENCES

BRINSUPRI (BRENSOCATIB ) APPROVED BY FDA AS FIRST AND ONLY TREATMENT FOR NON-CYSTIC FIBROSIS BRONCHIECTASIS; POSITIVE CHMP OPINION ADOPTED IN THE EUROPEAN UNION AND APPLICATION ACCEPTED IN JAPAN BRINSUPRITOTAL REVENUE OF $ 28.1 MILLION FOR THE THIRD QUARTER OF 2025 ARIKAYCE (AMIKACIN LIPOSOME INHALATION SUSPENSION) TOTAL REVENUE OF $ 114.3 MILLION FOR THE THIRD QUARTER OF 2025, REFLECTING 22% GROWTH OVER THE THIRD QUARTER OF 2024 COMPANY RAISES 2025 GLOBAL ARIKAYCE REVENUE GUIDANCE RANGE TO $420 MILLION TO $430 MILLION, REFLECTING DOUBLE-DIGIT GROWTH COMPARED TO 2024 TOPLINE DATA READOUT ANTICIPATED FOR PHASE 2B BIRCH STUDY OF BRENSOCATIB IN PATIENTS WITH CRSSNP BY EARLY JANUARY 2026 PHASE 2B CEDAR STUDY OF BRENSOCATIB IN PATIENTS WITH HS NOW FULLY ENROLLED, WITH TOPLINE DATA ANTICIPATED IN THE FIRST HALF OF 2026 PALM-ILD PHASE 3 STUDY OF TPIP FOR PH-ILD EXPECTED TO INITIATE IN THE FOURTH QUARTER OF 2025; ADDITIONAL PHASE 3 STUDIES PLANNED FOR PAH, PPF, AND IPF IN 2026 BRIDGEWATER, N.J. , OCT. 30, 2025 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025 AND PROVIDED A BUSINESS UPDATE.

INSMED REPORTS THIRD-QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

INSMED LEADSSCIENCETOP EMPLOYERS LIST FOR FIFTH YEAR IN A ROW BRIDGEWATER, N.J. , OCT. 23, 2025 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY ANNOUNCED THAT IT HAS EARNED THE HIGHEST RANKING INSCIENCE'S 2025 TOP EMPLOYERS SURVEY.

INSMED RANKS NO. 1 ON SCIENCE'S 2025 TOP BIOPHARMA EMPLOYERS LIST

 IF APPROVED, BRINSUPRI WOULD BE THE FIRST AND ONLY TREATMENT IN THE EUROPEAN UNION FOR NON-CYSTIC FIBROSIS BRONCHIECTASIS (NCFB) AND THE FIRST-IN-CLASS DPPI INHIBITOR TARGETING NEUTROPHILIC INFLAMMATION  BRINSUPRI WAS REVIEWED UNDER CHMP'S ACCELERATED ASSESSMENT PATHWAY AS IT IS CONSIDERED OF MAJOR INTEREST FOR PUBLIC HEALTH AND THERAPEUTIC INNOVATION  BRIDGEWATER, N.J. , OCT. 17, 2025 /PRNEWSWIRE/ --INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY ANNOUNCED THAT THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OF THE EUROPEAN MEDICINES AGENCY (EMA) HAS ADOPTED A POSITIVE OPINION RECOMMENDING APPROVAL OF ITS DPP1 INHIBITOR BRINSUPRI (BRENSOCATIB 25 MG TABLETS) FOR THE TREATMENT OF NON-CYSTIC FIBROSIS BRONCHIECTASIS (NCFB) IN PATIENTS 12 YEARS OF AGE AND OLDER WITH TWO OR MORE EXACERBATIONS IN THE PRIOR 12 MONTHS.

CHMP RECOMMENDS EU APPROVAL OF BRINSUPRI (BRENSOCATIB) FOR THE TREATMENT OF NON-CYSTIC FIBROSIS BRONCHIECTASIS

DATA ON STRUCTURAL LUNG CHANGES FROM A HIGH-RESOLUTION CT SUBSTUDY TO BE PRESENTED AS LATE-BREAKER ADDITIONAL ANALYSES WILL HIGHLIGHT EFFICACY, SYMPTOM REDUCTION, AND BIOMARKER SUPPRESSION IN PATIENTS WITH NON-CYSTIC FIBROSIS BRONCHIECTASIS BRIDGEWATER, N.J. , OCT. 16, 2025 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY ANNOUNCED THAT IT WILL PRESENT SIX ABSTRACTS FROM THE PHASE 3 ASPEN STUDY OF BRINSUPRI (BRENSOCATIB) AT CHEST 2025, THE AMERICAN COLLEGE OF CHEST PHYSICIANS ANNUAL MEETING, TAKING PLACE OCTOBER 19 - OCTOBER 22, 2025, IN CHICAGO, IL.

INSMED TO PRESENT MULTIPLE ANALYSES FROM PHASE 3 ASPEN STUDY AT THE AMERICAN COLLEGE OF CHEST PHYSICIANS ANNUAL MEETING 2025

BRIDGEWATER, N.J. , OCT. 15, 2025 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY ANNOUNCED THAT IT WILL RELEASE ITS THIRD-QUARTER 2025 FINANCIAL RESULTS ONTHURSDAY, OCTOBER 30, 2025.

INSMED TO HOST THIRD-QUARTER 2025 FINANCIAL RESULTS CONFERENCE CALL ON THURSDAY, OCTOBER 30, 2025

DATA FROM PHASE 2B STUDY OF TREPROSTINIL PALMITIL INHALATION POWDER IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION TO BE PRESENTED AT LATE-BREAKING ALERT SESSION  NEW ANALYSIS FROM PHASE 3 ASPEN TRIAL EXAMINES EFFICACY AND SAFETY OF BRENSOCATIB IN JAPANESE PATIENTS WITH NON-CYSTIC FIBROSIS BRONCHIECTASIS BY REDUCTION OF EXACERBATION HISTORY BRIDGEWATER, N.J. , SEPT. 22, 2025 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY ANNOUNCED THAT IT WILL PRESENT SEVEN ABSTRACTS FROM ACROSS ITS LATE-STAGE PORTFOLIO AT THE EUROPEAN RESPIRATORY SOCIETY (ERS) 2025 CONGRESS, TAKING PLACE SEPTEMBER 27  OCTOBER 1, 2025, IN AMSTERDAM.

Insmed Incorporated

INSM

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Insmed Incorporated

INSM.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

INSM